HER2DX predicts outcomes in early HER2+ breast cancer, adding prognostic value beyond standard clinical-pathologic factors. Dr. Sara Tolaney explores how DESTINY-Breast09 may reshape first-line treatment in HER2+ metastatic breast cancer. Dr. Maryam Lustberg discusses real-world T-DXd use, biomarkers, and resistance in metastatic breast cancer care. AI-enhanced HER2 scoring improves accuracy and may expand patient access to HER2-targeted therapies in breast cancer care. Dr. Kelly McCann of UCLA details HER2-positive breast cancer sequencing and toxicity management. Top research highlights from ESMO Breast Cancer 2025 showcase advances in treatment and care for patients with breast cancer. AI-assisted platform boosts accuracy in identifying HER2-low breast cancer, improving access to targeted therapies. Cross-resistance data raise questions about sequencing ADCs in mBC; Dr. Lustberg discusses real-world outcomes and next steps DESTINY-Breast09 shows promising PFS with T-DXd + pertuzumab vs THP in HER2+ MBC, but safety and sequencing raise questions.
Dr. Shatsky weighs DESTINY-Breast09 findings and highlights the need to balance efficacy with long-term quality of life.
HER3-DXd shows promise for CNS metastases in breast and lung cancer in the TUXEDO-3 trial, including patients with LMD. Dr. Lustberg discusses DESTINY-Breast09 and the potential shift to T-DXd + pertuzumab in HER2+ mBC first-line treatment. Stephanie Graff, MD, reviews top ASCO25 breast cancer trials, including ASCENT-04, DESTINY-Breast09, and SERENA-6.
Dr. Gradishar discusses how tolerability, toxicity, and NCCN guidelines shape HER2+ breast cancer treatment decisions.
Dr. William Gradishar discusses treatment sequencing strategies for HER2+ metastatic breast cancer at ASCO 2025. T-DXd plus pertuzumab significantly improves PFS vs THP in HER2+ mBC, per interim results from DESTINY-Breast09. THP delivers similar pCR and better tolerability than TCbHP for HER2+ early breast cancer, per phase 3 neoCARHP trial. T-DXd improves PFS and cORR over chemo in HER2-low/ultralow HR+ mBC, regardless of PI3K, ESR1, or BRCA1/2 mutations. T-DXd rechallenge after grade 1 ILD showed high success and prolonged benefit, with low recurrence and no grade 5 events. Trastuzumab rezetecan shows strong intracranial activity in HER2+ breast cancer with brain metastases in REIN trial.